Thermo Fisher Scientific
Search results
PPD is a global contract research organization (CRO) delivering clinical expertise for your product's success. Learn more about our life changing therapies.
PPD was founded by Fred Eshelman, Pharm.D., as a one-person consulting firm in 1985. The following year, he expanded the company's scope to include development services and relocated operations from Maryland to North Carolina.
Learn more about the PPD™ clinical research business of Thermo Fisher Scientific providing integrated drug development, laboratory and lifecycle management services.
Dec 8, 2021 · WALTHAM, Mass., Dec. 8, 2021 / PRNewswire / -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion.
PPD clinical development and analytical services enable customers to accelerate innovation and increase drug development productivity. Utilizing patient-centered strategies and data analytics, our capabilities cover multiple therapeutic areas and include early development, all phases of clinical development, peri- and post-approval, novel ...
MakingThe WorldHealthier,Cleaner and Safer Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers.
Apr 15, 2021 · Thermo Fisher is a leading supplier to the pharma and biotech industry, supporting research and development, clinical trials and production. PPD enhances Thermo Fisher's offering, bringing a proven drug development platform, excellent patient recruitment capabilities, strong laboratory services and a complementary reputation for excellent ...
PPD | 583,951 followers on LinkedIn. Helping deliver life-changing therapies | PPD is part of Thermo Fisher Scientific, the world leader in serving science.
Dec 8, 2021 · Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed its acquisition of PPD, Inc. (Nasdaq: PPD), a leading global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion.
PPD enhances Thermo Fisher’s offering, bringing a proven drug development platform, excellent patient recruitment capabilities, strong laboratory services and a complementary reputation for excellent quality and service.
